Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

Inclusion criteria

• ✓. Voluntarily participates in the study and provides written informed consent;
• ✓. Aged 18-75 years, with no restriction on sex;
• ✓. Histologically or cytologically confirmed diagnosis of non-small-cell lung cancer (NSCLC);
• ✓. Has not received prior systemic therapy and is willing to undergo neoadjuvant treatment for stage cⅡ-Ⅲ (N2a) disease, according to the 9th edition of the AJCC staging system (Appendix 1);
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (see Appendix 2 for scoring criteria);
• ✓. Considered by the thoracic surgeon to have adequate pulmonary reserve to tolerate the planned lung resection;
• ✓. Availability of tumor tissue prior to enrollment for pathological confirmation of EGFR/ALK wild-type status and PD-L1 expression assessment;
• ✓. No significant hematologic, cardiac, pulmonary, hepatic, renal, or immunologic dysfunction, with the following laboratory parameters meeting the specified criteria: